In conclusion, our findings offer valuable insights into the interplay between somatotroph adenoma SRL therapy and the immune microenvironment, including the identification of the CD68+/CD8+ ratio as a potential biomarker for treatment resistance in SRL‐naïve patients. The gene discussed is CD8A; the disease is growth hormone-secreting pituitary adenoma.